07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

BACcel system diagnostic data

A study in 56 spiked blood culture samples showed that Accelr8's BACcel rapid diagnostic system had 100% sensitivity and 94% specificity for detecting multi-drug resistant clinical isolates of Enterobacteriaceae bacteria. Furthermore, Accelr8 said the results...
07:00 , May 21, 2012 |  BC Week In Review  |  Company News

Accelr8 Technology, Denver Health & Hospital Authority diagnostic, infectious news

Accelr8 and Denver Health received notice that the U.S. Department of Defense's Defense Medical Research and Development Program (DMRDP) awarded the partners $2 million to develop Accelr8's BACcel same-shift rapid diagnostic system to detect wound...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Company News

Accelr8 Technology, Novartis deal

The parties extended to Sept. 30 the evaluation period for a deal under which Novartis' Novartis Vaccines and Diagnostics Inc. subsidiary is evaluating Accelr8's BACcel rapid diagnostic system in identifying the type and quantity of...
07:00 , May 23, 2011 |  BC Week In Review  |  Clinical News

BACcel system: Pilot trial data

A pilot trial analyzing 77 bronchoalveolar lavage (BAL) samples from 35 ICU patients at high-risk of developing pneumonia showed that Accelr8's BACcel rapid diagnostic system had 86% sensitivity and 97% specificity for detecting any of...
01:09 , May 18, 2011 |  BC Extra  |  Clinical News

Accelr8 reports data for pneumonia diagnostic

Accelr8 Technology Corp. (NYSE-A:AXK) reported data from a pilot trial of its BACcel rapid diagnostic system to analyze 77 bronchoalveolar lavage (BAL) samples from 35 ICU patients at high-risk of developing pneumonia. BACcel had 86%...